Expression of FasL and perforin/granzyme B mRNA in chronic hepatitis B virus infection

Journal of Viral Hepatitis

Volumn 11, Issue 2, 2004, Pages 130-135

  Lee, J Y ^a   Chae, D W ^a   Kim, S M ^a   Nam, E S ^a   Jang, M K ^b   Lee, J H ^a   Kim, H Y ^a   Yoo, J Y ^a  

^a Hallym University Medical Center   (South Korea)

^b Asan Medical Center   (South Korea)

Author keywords

Apoptosis; Chronic hepatitis B; Fas ligand; Granzyme B; Perforin

Indexed keywords

ALANINE AMINOTRANSFERASE; FAS LIGAND; GRANZYME B; MESSENGER RNA; PERFORIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER CELL; LIVER INJURY; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALANINE TRANSAMINASE; APOPTOSIS; BIOPSY; CYTOTOXICITY, IMMUNOLOGIC; DNA FRAGMENTATION; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION; GRANZYMES; HEPATITIS B ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; IN SITU NICK-END LABELING; LIVER; MEMBRANE GLYCOPROTEINS; PORE FORMING CYTOTOXIC PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERINE ENDOPEPTIDASES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 1642367212     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2003.00486.x     Document Type: Article

References (31)

1. Koziel MJ. Immunology of viral hepatitis. Am J med 1996; 100: 98-109.
2. Peters M, Vierling J, Gershwin ME, Milich D, Chisari FV, Hoofnagle JH. Immunology and the liver. Hepatology 1991; 13: 977-994.
3. Rosser BG, Gores G. Liver cell necrosis: cellular mechanisms and clinical implications. Gastroenterology 1995; 108: 252-275.
4. Shresta S, Pham CTN, Thomas DA, Graubert TA, Ley TJ. How do cytotoxic lymphocytes kill their targets. Curr Opin Immunol 1998; 10: 581-587.
5. Fukuda R, Ishimura N, Nguyen XT et al. Gene expression of perforin and granzyme A in the liver in chronic hepatitis C: comparison with peripheral blood mononuclear cells. Microbiol Immunol 1995; 39: 873-877.
6. Nakamoto Y, Guidotti LG, Pasquetto V, Schreiber RD, Chisari FV. Differential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice. J Immunol 1997; 158: 5692-5697.
7. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-1456.
8. Luo KX, Zhu YF, Zhang LX, HE HT, Wang XS, Zhang L. In situ investigation of Fas/FasL expression in chronic hepatitis infection and related liver disease. J Viral Hepat 1997; 4: 303-307.
9. Patel T, Steer CJ, Gores GJ. Apoptosis and the liver: a mechanism of disease, growth regulation, and carcinogenesis. Hepatology 1999; 30: 811-815.
10. Mochizuki K, Hayashi N, Kiramatsu N et al. Fas antigen expression in liver tissues of patients with chronic hepatitis B. J Hepatol 1996; 24: 1-7.
11. Tagashira M, Yamamoto K, Fujio K et al. Expression of perforin and Fas ligand mRNA in the liver of viral hepatitis. J Clin Immunol 2000; 20: 347-353.
12. Ibuki N, Yamamoto K, Yabushita K et al. In situ expression of Granzyme B and Fas-ligand in the liver of viral hepatitis. Liver 2002; 22: 198-204.
13. Strehlau J, Pavlakis M, Lipman M et al. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci USA 1997; 94: 695-700.
14. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520.
15. Ando K, Moriyama T, Guidotti LG et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 1993; 178: 1541-1554.
16. Ryo K, Kamogawa Y, Ikeda I et al. Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure. Am J Gastroenterol 2000; 95: 2047-2055.
17. Nelson DR, Marousis CG, Davis GL et al. The role of hepatitis C virus-specific cytotoxic T lymphocyties in chronic hepatitis C. J Immunol 1997; 158: 1473-1478.
18. Ando K, Hiroishi K, Kaneko T et al. Perforin, fas/fas ligand, and TNF-α pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J Immunol 1997; 158: 5283-5291.
19. Kaser A, Enrich B, Ludwiczek O, Vogel W, Tilg H. Interferon-alpha enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway. Clin Exp Immunol 1999; 118: 71-77.
20. Galle PR, Hofmann WJ, Walczak H et al. Involvement of the CD95(APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995; 182: 1223-1230.
21. Rodrigues CM, Brites D, Serejo F, Costa A, Ramalho F, Moura MC. Apoptotic cell death does not parallel other indicators of liver damage in chronic hepatitis C patients. J Viral Hepat 2000; 7: 175-183.
22. Taieb J, Mathurin P, Poynard T, Gougerot-Pocidalo MA, Chollet-Martin S. Raised plasma soluble fas and fas ligand in alcoholic liver disease. Lancet 1998; 351: 1930-1931.
23. Taya N, Torimoto Y, Shindo M, Hirai K, Hasebe C, Kohgo Y. Fas-mediated apoptosis of peripheral blood mononuclear cells in patients with hepatitis C. Br J Haematol 2000; 110: 89-97.
24. Hodgson PD, Grant MD, Michalak TI. Perforin and Fas/Fas ligand-mediated cytotoxicity in acute and chronic woodchuck viral hepatitis. Clin Exp Immunol 1999; 118: 63-70.
25. Tordjmann T, Soulie A, Guettier C et al. Perforin and granzyme B lytic protein expression during chronic viral and autoimmune hepatitis. Liver 1998; 18: 391-397.
26. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 1997; 3: 409-413.
27. Kagi D, Ledermann B, Burki K et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994; 369: 31-37.
28. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25-36.
29. Balkow S, Kersten A, Tran TT et al. Concerted action of the FasL/ Fas and perforin/granzyme A and B pathways is mandatory for the development of early viral hepatitis but not for recovery from viral infection. J Virol 2001; 75: 8781-8791.
30. Kagi D, Seiler P, Pavlovic J et al. The roles of perforin- and Fas- dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. Eur J Immunol 1995; 25: 3256-3262.
31. Sharma VK, Bologa RM, Li B et al. Molecular executors of cell death-differential intrarenal expression of Fas ligand, Fas, granzyme B, and perforin during acute and/or chronic rejection of human renal allografts. Transplantation 1996; 62: 1860-1866.